UroGen Pharma Ltd.
NASDAQ:URGNBiotechnology
-$0.40 today
- Market cap
- $1.46B
- Beta
- 1.62
- P/E (TTM)
- -12.2
- EPS (TTM)
- -$2.65
Volume 1.14M
Average 0.79M
URGN Change in Working Capital
Cash absorbed or released by changes in receivables, inventory, payables, and other operating balances.
UroGen Pharma Ltd.NASDAQ: URGN
Change in Working Capital · Q1 FY2026 · quarter ended Mar 2026
Change in working capital growth accelerates
Q1 FY2026 change in working capital of $30.08M (cash outflow) rose 1063.2% year over year, ahead of the -938.3% change in trailing-twelve-month change in working capital. Sequentially, it rose 64.7% from the prior quarter. Over 3 fiscal years it compounded at +64.2% a year.
Context
- Change in working capital amounted to 25.4% of revenue in FY2025, up 20.0 pp from a year earlier.
- Change in working capital increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +1063.2% holds above the trailing-twelve-month pace of -938.3%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Change in Working Capital history
USD · from the cash flow
- Latest · FY2025
- (27.91M) USD
- Year-over-year change
- -665.9%
| Period | Period end | Change in Working Capital | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (27.91M) | -665.9% |
| FY2024 | 2024-12-31 | 4.93M | +47.9% |
| FY2023 | 2023-12-31 | 3.34M | +152.9% |
| FY2022 | 2022-12-31 | (6.31M) | +51.9% |
| FY2021 | 2021-12-31 | (13.11M) | — |
Change in Working Capital vs competitors
How URGN compares with its peers on the latest reported figures
- URGN's LTM Mar 2026 change in working capital of $53.19M is the largest of the 3 companies compared; the peer median is $2.29M.
- Its year-over-year change of -938.3% is the lowest of 3, against a peer median of +36.2%.
- Change in working capital amounts to 37.9% of revenue for URGN, versus a peer median of 19.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $53.19M | -938.3% | +64.2% | 37.9% | |
| LTM Mar 2026 | $5.78M | +183.1% | — | — | |
| LTM Sep 2026 | $1.2M | -110.7% | -20.0% | 19.4% | |
| Peer median (excluding URGN) | $2.29M | +36.2% | -20.0% | 19.4% | |
Competitors are the stored peer set for URGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (110.82M) | (109.78M) | (102.24M) | (126.87M) | (153.49M) |
| Depreciation & Amortization | 1.77M | 1.82M | 1.71M | 1.19M | 2.41M |
| Deferred Income Tax | 15.32M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 23.11M | 10.58M | 9.34M | 13.11M | 11.96M |
| Change in Working Capital | (13.11M) | (6.31M) | 3.34M | 4.93M | (27.91M) |
| Accounts Receivables | (4.67M) | (987K) | (2.74M) | (4.86M) | (12.78M) |
| Inventory | (2.87M) | (362K) | (1.35M) | (3.55M) | (7.24M) |
| Accounts Payables | 2M | 281K | 4.16M | 10.89M | 286K |
| Other Working Capital | (7.57M) | (5.24M) | 3.27M | 2.45M | (8.18M) |
| Other Non-Cash Items | (1.18M) | 16.13M | 11.48M | 10.88M | 4.59M |
| Operating Cash Flow | (84.89M) | (87.56M) | (76.38M) | (96.77M) | (162.44M) |
| Capital Expenditures | (752K) | (254K) | (194K) | (295K) | (289K) |
| Acquisitions (Net) | (4.82M) | (1.31M) | 0 | 0 | 0 |
| Purchases of Investments | (51.9M) | (63.01M) | (49.83M) | (128.02M) | (77.4M) |
| Sales of Investments | 56.72M | 64.32M | 49.07M | 107.71M | 139.25M |
| Other Investing Activities | 4.82M | 1.31M | 0 | 0 | 0 |
| Investing Cash Flow | 4.07M | 1.06M | (953K) | (20.61M) | 61.56M |
| Debt Repayment | 0 | 95.78M | 0 | 24.49M | (1.86M) |
| Common Stock Issued | (83K) | 1.35M | 67.36M | 151.17M | 41.77M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 72.4M | (160K) | 49.57M | 18.96M | 0 |
| Financing Cash Flow | 72.32M | 97.13M | 116.93M | 194.62M | 39.92M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (8.5M) | 10.64M | 39.6M | 77.24M | (60.97M) |
| Free Cash Flow | (85.64M) | (87.81M) | (76.57M) | (97.06M) | (162.73M) |
UroGen Pharma Ltd.
NASDAQ:URGN
Intrinsic Alpha fair value
Locked
Current Price
$29.79
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.